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Abstract: Background. In squamous cell carcinoma of the
oral cavity (SCCOC), regular follow-up comprises 5 years of
prescheduled visits, irrespective of tumor stage/classiﬁcation
and/or treatment. We analyzed our standard treatment and fol-
low-up protocol in patients with a preoperative clinically nega-
tive neck (cN0) in SCCOC.
Methods. This is a retrospective chart analysis. Inventariza-
tion of treatment, occult metastatic spread, and follow-up were
performed.
Results. In all, 197 patients were included. The occult met-
astatic rate was 24%. Eighty-three percent of recurrent disease
presented within 2 years. Fifty-three percent of the patients
with recurrent disease visited their physician outside presched-
uled control visits.
Conclusions. Ultrasound-guided ﬁne-needle aspiration cy-
tology currently is 1 of the most reliable staging techniques in
cN0 SCCOC. Regular follow-up could perhaps be limited from
5 to 2 years of prescheduled follow-up visits. VC 2010 Wiley
Periodicals, Inc. Head Neck 33: 1400–1405, 2011
Keywords: neck dissection; follow-up; clinically negative neck;
squamous cell carcinoma; oral cavity
One of the most controversial items in head and
neck remains the treatment of the clinically negative
neck (cN0) in squamous cell carcinoma of the oral
cavity (SCCOC) attributed to the presence of occult
metastases. Control of the primary tumor can usually
be achieved by surgery and, in some cases, by radio-
therapy. Tumor treatment failure is often attributed
to metastatic spread to cervical lymph nodes, reduc-
ing survival by approximately 50%.1–3 Management
of the cN0 neck is therefore considered crucial. Three
options are available: elective neck dissection, pri-
mary radiotherapeutic treatment, or a ‘‘wait-and-see’’
policy. The rationale behind the latter is that 60% to
80% of patients who undergo elective neck dissection
are in fact being overtreated, leading to increased
morbidity. A wait-and-see policy requires careful mon-
itoring of the neck over time, in combination with
ultrasound and/or ultrasound-guided ﬁne-needle aspi-
ration cytology (FNAC). Should a positive lymph node
be detected during follow-up, different types of sal-
vage neck dissection can be performed. With this
strategy, some studies have found recurrence rates
comparable to those for elective treatment of the
neck.4,5
However, other studies (which did not include ultra-
sound-guided FNAC during follow-up for the neck)
reported lower survival rates in patients following a
wait-and-see policy,6,7 compared with patients treated
by elective neck dissection.
Given these considerations, we have ﬁrst evaluated
the results of our standard surgical treatment with
elective neck dissection for patients suffering from
SCCOC. Furthermore, we especially focused on the re-
currence rate of regional disease following elective neck
dissection, with special emphasis on the follow-up
schedule that is advocated in the national guideline for
oral carcinoma issued by the Dutch Cancer Society.
MATERIALS AND METHODS
In this retrospective study, the medical records of all
consecutive patients with histologically proven
SCCOC, who presented at the Radboud University
Nijmegen Medical Center between January 1, 1992,
and December 1, 2004, were reviewed. Patients with
a cN0 neck staged through palpation and ultrasound
who underwent selective neck dissection of levels I–
III (supraomohyoidal neck dissection [SOHND]), as
described by Medina et al,8 as a staging procedure
and as part of their treatment, were included. In all
cases, a preoperative ultrasound examination of the
Correspondence to: B. M. Wensing
VC 2010 Wiley Periodicals, Inc.
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neck was performed. If a suspicious lymph node (or
nodes) with a minimum diameter >5 mm was found
by ultrasound, ﬁne-needle aspiration cytology was
performed. A conventional chest x-ray was performed
in every patient. CT and/or MRI scanning were per-
formed only in case of doubts concerning primary tu-
mor extension (eg, bone involvement). Patients who
had had head and neck squamous cell carcinoma
(HNSCC) 5 years prior to their current treatment or
who had received radiotherapeutic or chemotherapeu-
tic treatment for any kind of disease during this pe-
riod were excluded.
Surgery was performed by 5 experienced head
and neck surgeons. In the majority of cases, a frozen
stage section of the neck specimen was performed
during the operation: suspicious nodes and/or the
largest jugulodigastric and most distal jugulo-omo-
hyoid node were sampled. If frozen stage section dur-
ing the operation revealed metastatic disease,
selective neck dissection of levels I–III was routinely
extended to a modiﬁed radical neck dissection
(MRND), encompassing levels I–V. After the resection
specimen had undergone standardized marking, it
was sent to the department of pathology where it was
examined using standardized sectioning and hema-
toxylin and eosin staining.
The detection of 2 histopathologically conﬁrmed
metastatic lymph nodes and/or the presence of extrac-
apsular spread (ECS) were absolute indications for
postoperative radiotherapeutic treatment. Tumor-
positive resection margins were an indication for radio-
therapeutic treatment of the primary site. Relative
indications for postoperative radiotherapeutic treat-
ment were: tumor invasion of the mandible, 1 meta-
static lymph node, close resection margins (<5 mm),
angiolymphatic invasion, perineural invasion, and a
diffuse pattern of tumor growth. Local recurrence is
deﬁned as a recurrence at the original site within 5
years following therapeutic excision. After this time,
local tumor growth is considered to be a secondary pri-
mary tumor. Regional recurrence is deﬁned as meta-
static neck disease that does not affect structures of
the oral cavity. Distant metastasis is deﬁned as tumor
spread from the primary tumor to distant organs or
distant lymph nodes (eg, not the neck).
The recommended follow-up comprises 5 years of
regular prescheduled visits.9 The minimum follow-up
period in this study was 5 years. Our standard follow-up
schedule consisted of visits every 2 months during the
ﬁrst year after surgical treatment, every 3 months dur-
ing the second year, every 4 months during the third
year, and every 6 months during the fourth and ﬁfth
years. Hereafter, in the absence of any signs of recur-
rence or metastatic spread, patients were discharged.
Survival curves were estimated with the Kaplan–
Meier approach based on overall survival (OS) and
disease-free survival (DFS). OS was calculated from
the date that patients were surgically treated,
whereas DFS was calculated using the date of detec-
tion of recurrent disease. Log-rank tests were used to
compare the study groups.
RESULTS
In all, 197 patients were included: 125 men (63%) and
72 women (37%). Their age ranged from 27 to 90
years at the time of their operation (mean age, 62
years). Distributions of T and N classiﬁcations and tu-
mor locations are shown in Table 1.
All patients were preoperatively staged cN0
through palpation and ultrasound. In 50 of 197 cases
(25%; 220 necks) ultrasound-guided FNAC was per-
formed. A total of 48 neck specimens (24% of patients)
showed regional metastatic spread during postopera-
tive histopathologic examination; 1 specimen was
bilaterally positive (49 pNþ necks).
In a total of 30 T3 and T4 tumors, 5 times a
Thiersch graft was used to close the site of the
excised primary tumor. In 16 cases, extensive recon-
structive surgery of the primary site was performed:
10 free-ﬂap soft tissue transfers were performed, as
were 6 bone reconstructions, combined with soft tis-
sue reconstructions. In 9 of these 30 cases, the wound
could be closed primarily.
In total, 76 metastases were found in 48 patients.
No metastatic nodes were found in additionally
resected neck levels (levels IV and V), performed after
positive frozen stage section. Histopathologic staging
of the neck yielded the following ﬁndings: 149 pN0,
33 pN1, 14 pN2b, and 1 pN2c (68 stage I, 63 stage II,
36 stage III, and 30 stage IVA tumors).
Twenty-two patients had absolute indications for
postoperative radiotherapeutic treatment based on
their neck staging (7 patients had 1 metastasis with
ECS, 4 patients had 2 metastatic lymph nodes with
Table 1. Preoperative clinical TNM classiﬁcation and location of 197 primary tumors.
Clinical TNM
classiﬁcation
No. of tumors by tumor site
TotalRetromolar trigone Floor of the mouth Lateral tongue Alveolar process Buccal mucosa
TxN0M0 0 1 1 0 0 2
T1N0M0 8 18 33 2 1 62
T2N0M0 7 47 41 4 4 103
T3N0M0 0 6 10 1 0 17
T4N0M0 5 4 0 4 0 13
Total 20 76 85 11 5 197
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ECS, and 11 patients had >2 tumor-positive nodes).
Fifteen of these 22 patients actually received postop-
erative radiotherapeutic treatment (1 of the remain-
ing 7 patients died shortly after surgery as a result of
massive aspiration, and the condition of the other 6
patients was too poor to administer adequate treat-
ment). Sixty-two patients received radiotherapeutic
treatment based on primary tumor characteristics.
Forty patients (20%) suffered from local, regional,
or distant recurrence. For an overview of their respec-
tive cT and pTN stages/classiﬁcations, see Table 2.
Fourteen of these patients initially presented with re-
gional recurrence (7% of 197 patients). Of 149 pN0
necks, 9 patients (6%) developed initial regional
recurrent disease, whereas 3 of the 48 patients with
pNþ necks (6%) initially presented with regional re-
currence. In 1 of these 12 patients, level IV (combined
with level III) showed metastatic disease. Two more
patients presented with regional recurrent disease,
but also had a secondary primary tumor and the ori-
gin of regional disease was unclear. Six of 30 patients
who had undergone extensive reconstructive surgery
had recurrence: 3 local recurrences and 3 regional
recurrences.
Twenty-four patients initially presented with a
local recurrence (12% of 197 patients), whereas the
remaining 2 patients had distant metastatic disease,
only without locoregional residual disease.
Fourteen of the 40 patients with recurrent disease
were palliatively treated (35%). Nineteen patients with
recurrent disease underwent salvage surgery, and 9 of
these patients also received radiotherapeutic treatment.
Six patients received curative radiotherapeutic treat-
ment. One patient was treated in a different hospital
for recurrent disease and was lost to follow-up.
Of the 19 patients treated by salvage surgery, with
or without additional radiotherapeutic treatment, 11
died of recurrent disease (58%), a further 2 died of a
second primary tumor, and 1 died of an unrelated dis-
ease. Five of these 19 patients were disease-free at the
end of follow-up. All 6 patients treated with curative
intent by radiotherapy died of recurrent disease. In
total, 17 of 25 curatively treated patients (68%) died
because of recurrent disease, 5 were alive and free of
disease at the end of follow-up, 2 died from second pri-
mary tumors, and 1 patient died as a result of cardio-
vascular disease. This means that 20 of 25 patients
(80%) were dead within 5 years of treatment for recur-
rent disease; in other words, 78% of patients presenting
with recurrent disease died a tumor-related death.
The mean follow-up duration was 46 months (3.8
years; median, 60 months; minimum, 0 months; maxi-
mum, 60 months). The mean time between primary
curative surgery and appearance of recurrent disease
was 15 months (1.25 years; median, 10 months; mini-
mum, 2 months; maximum, 58 months). Eighty per-
cent of recurrences appeared within 20 months after
primary curative surgery, 83% within 2 years from
treatment, and 90% within 3 years from treatment.
In terms of presentation of recurrent disease, 16
patients (40%) presented with signs of recurrent dis-
ease during prescheduled routine visits. Twenty-one
patients (53%) visited their oncologist at their own
request with symptoms related to their recurrent dis-
ease, and for 3 patients (7%) it was not possible to as-
certain when the recurrent disease was detected in
these patients.
Finally, Figures 1 and 2 show the overall survival
and disease-free survival, respectively, in cN0 SCC of
the oral cavity. Five-year overall survival was 67%
(Figure 1). Five-year disease-free survival was 93, 80,
85, and 63% in stages I–IVA, respectively (Figure 2).
DISCUSSION
Our results conﬁrm that, to date, selective neck dis-
section of levels I–III (formerly SOHND) remains the
most important diagnostic tool in clinically N0 squa-
mous cell carcinoma of the oral cavity. In a widely
accepted proposed treatment strategy, Weiss et al10
estimate that if there is a >20% probability of ﬁnding
occult metastatic spread during histopathologic exam-
ination of cN0 necks in SCC of the oral cavity, elective
treatment of the neck should be performed. The pre-
operative use of ultrasound-guided FNAC combined
with standard histopathologic examination of the dis-
section specimen revealed a comparable percentage of
occult metastases, compared with preoperative stag-
ing by CT, MRI, or 18F-ﬂuorodeoxyglucose positron
emission tomography (FDG–PET) followed by histopa-
thologic staging,4,5,11–15 although its use is still not
widely accepted. This ﬁnding has been previously
Table 2. Distribution of clinical and pathological TNM stages in 40 patients with recurrent disease.
cTNM
No. of tumors
TotalpT1N0 pT2N0 pT3N0 pT4N0 pT1N1 pT2N1 pT4N1 pT2N2b pT3N2b pT4N2b
TxN0M0 0 0 0 1 0 0 0 0 0 0
T1N0M0 4 3 0 1 2 0 0 0 0 0
T2N0M0 2 10 0 0 1 4 0 5 0 0
T3N0M0 0 1 1 0 0 0 0 0 1 0
T4N0M0 0 1 0 1 0 0 1 0 0 1
Total 6 15 1 3 3 4 1 5 1 1 40
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mentioned by authors, such as van den Brekel et al4,5
and Nieuwenhuis et al,16 who even propose a wait-
and-see policy for a cN0 neck in certain cases of head
and neck SCC.
In the current study, the percentage of occult met-
astatic spread and recurrent disease is comparable to
previously published data.12,14,17
Six percent of patients with a pN0 neck as well as
6% of patients with a pNþ neck developed an initial
regional recurrence. If more sensitive histopathologic
techniques would have been used (for instance, the
use of immunohistochemistry and improved serial
sectioning), perhaps more pNþ necks would have
been identiﬁed. Selective neck dissection would then
have been even more therapeutic than we think since
those necks, scored pN0, do not show more recurrent
disease than pNþ necks, of which most are addition-
ally treated.
We found no so-called skip metastases in our neck
dissection specimens: of course, aforementioned limi-
tations of standard histopathologic workup could also
inﬂuence these numbers. Furthermore, only 1 initial
regional recurrence involved level IV and, thus, in
this group of patients, addition of level IV to standard
treatment of the neck (as proposed by a number of
authors21,22) does not seem justiﬁed. With postopera-
tive radiotherapeutic treatment on indication, this
group with cN0 SCCOC has a 5-year DFS of 83%.
The main goal of strict follow-up schedules would
be to signal recurrent disease at an early stage, pref-
erably leading to more successful salvage treatment.
More than half of the patients who had recurrent dis-
ease made an extra appointment that led to the detec-
tion. Despite salvage treatment, however, survival
rates decline dramatically with recurrent disease.
This leads to questions regarding the follow-up sched-
ule proposed in the Dutch national guideline for oral
cavity carcinoma issued by the Dutch Cancer Society.
For example, could prescheduled visits be limited?
Could patients be better informed about the signs of
possible recurrent disease and could regular visits
even be abandoned?
In terms of costs, 76% of patients in this study
with cN0 oral cavity carcinoma underwent elective
treatment of the neck without any signs of postopera-
tive metastatic spread. In all, 124 of 197 patients
(63%) remained disease-free postoperatively during
follow-up. In other words, 63% of patients were inten-
sively followed during the course of 5 years, involving
high costs. Van den Brekel et al5 showed that in a
group of mainly T1 and T2 oral tumors strict follow-
up of the neck using ultrasound-guided FNAC every
2 to 5 visits (prescheduled visits every 4–8 weeks dur-
ing the ﬁrst year) could possibly replace elective neck
dissection. In terms of our cohort, this would imply a
total of 992 visits (8 visits per year on average), 310
ultrasounds (2.5 per year on average), and at least as
many FNA biopsies in 124 disease-free patients dur-
ing the ﬁrst year of follow-up alone. Of course, in the
case of more advanced c- and pTN classiﬁcations/
stages, especially after extensive reconstructive sur-
gery, we would prefer to see the patient on a frequent
basis because of a higher chance at postoperative
complications, a more prolonged recovery time, and
probably a higher need of psychosocial assistance.
The use and duration of follow-up has been ques-
tioned over the past few decades.23–27 Not only in
SCCOC, but also in other ﬁelds of medicine, has it
been shown that prescheduled follow-up visits prob-
ably do not improve chances at more early detection
FIGURE 2. Cumulative disease-free survival (months) related to
postoperative tumor stage. [Color ﬁgure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
FIGURE 1. Cumulative overall survival (months). [Color ﬁgure
can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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of recurrent disease. For instance, Ritoe et al27
showed that for laryngeal cancer treated primarily by
radiotherapy, only 2% of the total number of routine
visits revealed subclinical recurrent disease.
Follow-up after curative treatment of oral carci-
noma has a number of goals: early identiﬁcation of
recurrent disease or second primary tumors and early
curative treatment if possible, psychosocial help,
registration of late complications following therapy,
and evaluation of treatment. The value of follow-up
depends largely on certain parameters such as
whether a feasible treatment for recurrent disease is
available, whether early detection improves patient
survival, and whether there is a proper diagnostic
test (eg, good sensitivity/speciﬁcity) to rule out recur-
rent disease.
If we consider these parameters in the context of
our study, we have shown that our treatment for
recurrent disease saves only 22% of patients with
recurrent disease. Our study shows that over half of
patients with recurrent disease visit their treating
surgeon outside the prescheduled visits. Finally, the
diagnostic tests are the same as those used during
preoperative staging (inspection, palpation, and ultra-
sound-guided FNAC) and have the same limitations.
Five of 197 patients beneﬁted from the detection of
their recurrent disease as they survived after salvage
treatment. Three of these 5 recurrences were detected
at prescheduled follow-up visits, and 2 were detected
at extra visits at the patients’ own request. The
necessity and cost-effectiveness of a routine follow-up
schedule can thus be questioned, given that there is a
very limited effect on survival. However, from a psy-
chosocial perspective (for instance, rehabilitation after
extensive surgery), routine follow-up is, of course, val-
uable, as well as in the evaluation of complications
and treatment, especially in patients who underwent
extensive reconstructive surgery. Merkx et al9 have
already called for a reduction in the number of years
of follow-up from 10 to 5 years. We would suggest
that in curatively treated oral carcinoma, especially
in low-stage tumors, the number of years of routine
follow-up could perhaps be reduced from 5 to 2 years
as a next step in limiting prescheduled doctor visits.
CONCLUSIONS
Selective neck dissection of level I–III remains a reli-
able staging procedure in cN0 SCCOC and appears
to have therapeutic value as well. There is no indica-
tion for a level IV dissection. In case of recurrent
disease, survival rates drop dramatically despite
treatment. Long-term routine follow-up in case of
cN0 oral SCC is of very limited beneﬁt in terms of
patient survival and could perhaps be limited to 2
years, leading to more cost-effective postoperative
treatment.
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